

**LBT INNOVATIONS**

ACN 107 670 673

ASX / MEDIA RELEASE

The Manager
Company Announcements Office
ASX Limited

LBT INNOVATIONS GRANTED NEW PATENT FOR UNITED STATES

Adelaide, Australia, 11 November 2016: Australian medical technology company LBT Innovations Limited (ASX: LBT) has been issued a new patent by the US Patent and Trademark Office. The patent number is 9,470,624 and was issued on October 18, 2016. Confirmation of the patent approval has been received by LBT Innovations.

The patent covers the image capture and lighting apparatus of the Automated Plate Assessment System (APAS®) technology.

APAS® is a breakthrough artificial intelligence technology for the automated imaging, image analysis, interpretation and reporting of growth on microbiology culture plates after incubation. APAS® enables the faster diagnosis and reporting of infectious diseases.

This patent is the third successful application for United States patents and all three patents provide 20 years of patent protection. These three patents are part of a portfolio of four inventions related to APAS, for which LBT initiated intellectual property protection in 2011.

Developed by LBT Innovations, APAS® has been licensed on a global, exclusive basis to Clever Culture Systems AG, which is integrating APAS with laboratory robotic instrumentation. CCS is targeting to bring APAS to market as an automated stand-alone plate reader (APAS® Independence) followed by the integrated incubator (APAS® Incubot).

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improve patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has two world class-leading products in microbiology automation: MicroStreak®, which provides automated culture plate streaking and Automated Plate Assessment System (APAS®). Based on LBT's intelligent imaging and interpretative software, APAS® specifically addresses the automated imaging, analysis and interpretation of culture plates following incubation. LBT has entered into a joint venture Clever Culture Systems AG (CCS) with Hettich AG Switzerland to drive the commercialisation of APAS® products. LBT also has a third product in early development, WoundVue®, a proposed automated solution to assist in the management of chronic wounds.

For more information, see www.lbtinnovations.com

CONTACTS

LBT Innovations	Media Relations
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 (0)8 8227 1555 E: info@lbtinnovations.com	Rudi Michelson Monsoon Communications Tel: +61 (0)3 9620 3333 M: +61 (0) 411 402 737 E: rudim@monsoon.com.au